Q32 Bio priced a $200M public offering of common stock and pre-funded warrants at $18.25 a share, diluting existing shareholders a day after the stock surged 91% on positive alopecia data. The clinical-stage biotech plans to use the proceeds to advance bempikibart into later-stage trials.
Q32 Bio priced a $200M public offering at $18.25 a share, sending the stock down 6% after-hours after a 91% rally on positive clinical data.
"The positive data boosts the odds of success for bempikibart," Wells Fargo analyst Derek Archila said after upgrading the stock to Overweight from Equal Weight with a $66 price target, implying more than 200% upside from Monday's close.
The offering includes 6,027,399 common shares and pre-funded warrants for 4,931,506 shares. Morgan Stanley, Jefferies and Cantor are joint book-running managers, with Oppenheimer & Co. as an additional book-runner and H.C. Wainwright & Co. as lead manager. Underwriters have a 30-day option to purchase up to an additional $30M in shares.
The raise gives Q32 Bio capital to fund Phase 2b/3 trials of bempikibart, an anti-IL-7Rα antibody for severe alopecia areata. Monday's 36-week data from the SIGNAL-AA Phase 2a trial showed a 35% average reduction in scalp hair loss severity, with 40% of patients achieving at least 80% scalp coverage. The drug was well tolerated with no serious treatment-related side effects.
Oppenheimer called the data an "overwhelmingly positive derisking event" and raised its price target to $40 from $20. Mizuho's Joseph Catanzaro lifted his target to $36 from $14, citing "JAK-like to better" efficacy and a favorable safety profile. The new targets imply 68% to 209% upside from Monday's close.
The stock's after-hours decline reflects dilution concerns from the offering, which increases Q32 Bio's share count by roughly 11 million shares. Investors will watch for the company's next clinical update as it moves bempikibart into a registrational program.
This article is for informational purposes only and does not constitute investment advice.
